Enzyme replacement in Tay-Sachs disease.

Area of Science:

• Biochemistry
• Neurology
• Genetics

Background:

• Tay-Sachs disease is a rare genetic disorder caused by a deficiency of the enzyme hexosaminidase A.
• This deficiency leads to the accumulation of GM2 gangliosides in nerve cells, causing progressive neurodegeneration.
• Current treatment options for Tay-Sachs disease are limited.

Observation:

• Two individuals with Tay-Sachs disease, a 14-month-old child and a 7-week-old infant, received enzyme replacement therapy.
• Treatment involved weekly intrathecal injections of pure hexosaminidase A.
• Serum GM2 levels decreased significantly post-injection, but electron microscopy revealed no dissolution of brain GM2 cytoplasmic bodies.

Findings:

• Intrathecal hexosaminidase A administration effectively cleared GM2 from the serum.
• The treatment did not resolve the characteristic GM2 membranous cytoplasmic bodies in the brain.
• No significant clinical improvement was observed in either patient despite prolonged treatment.

Implications:

• Enzyme replacement therapy via intrathecal injection of hexosaminidase A is not a beneficial treatment for Tay-Sachs disease.
• The route of administration and the inability to clear brain-based GM2 deposits are significant limitations.
• Further research into alternative therapeutic strategies is warranted for Tay-Sachs disease.